Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: Methodological aspects and effects of antihypertensive treatment

Journal of Hypertension

Volumn 30, Issue 6, 2012, Pages 1241-1251

  Mancia, Giuseppe ^a   Facchetti, Rita ^a   Parati, Gianfranco ^a,b   Zanchetti, Alberto ^b,c  

^a SAN GERARDO HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

antihypertensive treatment; b blockers; blood pressure; calcium antagonists; hypertension

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE; LACIDIPINE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; EUROPE; FEMALE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 84861098550     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835339ac     Document Type: Article

References (22)

1. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dalhöf B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375:895-905.
2. Rothwell PM. Limitations oft he usual blood pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375:938-948.
3. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressure compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111:1777-1783.
4. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, et al., Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282:539-546.
5. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46:156-161.
6. RothwellPM,HowardSC,Dolan E, O'Brien E,Dobson JE,Dahlof B, et al., on behalf of the ASCOT-BPLA and MRC Trial investigators. Effects of b blockers and calciumchannel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9:469-480.
7. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensivedrug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375:906-915.
8. Zanchetti A. Wars, war games and dead bodies on the battle-field: variations on the theme of blood pressure variability. Stroke 2011; 42:2722-2724.
9. Zanchetti A, Bond MG, Henning M, Neiss A, Mancia G, Dal Palú C, et al., on behalf of the ELSA investigators. Calcium antagonist Lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation 2002; 106:2422-2427.
10. Mancia G, Parati G, Hennig M, Flatau B, Omboni S, Glavina F, et al., ELSA investigators. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001; 19:1981-1989.
11. Mancia G, Parati G, Bilo G, Maronati A, Omboni S, Baurecht H, et al. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens 2007; 25:1087-1094.
12. O'Brien E, Petrie J, Littler W, de Swiet M, Padfield PL, Altman DG, et al. An outline of the revised British Hypertension Society protocol for the evaluation of blood pressure measuring devices. J Hypertens 1993; 11:677-679.
13. O' Brien E, Atkins N, Stergiou G, Karpettas N, Parati G, Asmar R, et al., Working Group on Blood Pressure Monitoring of the European Society of Hypertension. European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults. Blood Press Monit 2010; 15:23-38.
14. Mancia G, Bertinieri G, Grassi G, Parati G, Pomidossi G, Ferrari AU, et al. Effects of blood pressure measurements by the doctor on patient's blood pressure and heart rate. Lancet 1983; 2:695-698.
15. Mancia G, Parati G, Pomidossi G, Grassi G, Casadei R, Zanchetti A. Alerting reaction and rise in blood pressure during measurements by physician and nurse. Hypertension 1987; 9:209-215.
16. Parati G, Pomidossi G, Casadei R, Mancia G. Lack of alerting reactions to intermittent cuff inflations during non invasive blood pressure monitoring. Hypertension 1985; 7:597-601.
17. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germanó G, et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007; 25:1105-1187.
18. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al., European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurements. J Hypertens 2003; 21:821-848.
19. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
20. Dalhöf B, Devereaux RB, Kjeldsen SE, Julius S, Beevers G, de FAire U, et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2005; 359:995-1003.
21. Carlberg B, Sammelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364:1684-1689.
22. Di Rienzo M, Grassi G, Pedotti A, Mancia G. Continuous vs intermittent blood pressure measurements in estimating 24-h average blood pressure. Hypertension 1983; 5:264-269.